The Michael J Fox Foundation reports that a new, second-round vaccine is being successfully tested in Austria. The researchers will present their findings at the World Parkinson Congress in Portland, OR later this month.
The foundation’s website reports: “The “boost” study builds on a first clinical trial, also funded by MJFF, where 24 participants with early-stage Parkinson’s received four doses of PD01A. That trial proved the treatment was safe and showed that half of the participants created alpha-synuclein antibodies. Within a year, however, each of the “responders” saw their levels of alpha-synuclein antibodies decline.
This follow-up trial gave each participant one more dose a year later to see if a “boost” would be safe and would raise antibody levels again. AFFiRiS reported today that the trial was safe; all 28 participants (22 from the first trial and six other people with PD) completed the study. In addition, more volunteers (86 percent) saw an antibody response. All responders from the first trial responded again, and some who did not respond in the first trial produced antibodies with the boost.
“This showed that the body is not desensitized to the vaccine and can produce alpha-synuclein antibodies again,” said Kuldip Dave, PhD, MJFF director of research programs who directs our alpha-synuclein portfolio. “And that you don’t have only one opportunity for treatment — that if you don’t produce antibodies with a first round of vaccine, you may with follow-up.” ”
Read on here: https://www.michaeljfox.org/foundation/news-detail.php?vaccine-for-parkinson-reports-positive-results-from-boost-study&et_cid=663718&et_rid=106459238&et_lid=https%253a%252f%252fwww.michaeljfox.org%252ffoundation%252fnews-detail.php%253fvaccine-for-parkinson-reports-positive-results-from-boost-studyem_cid=